ArticleJournal of nanobiotechnology2026
Multifunctional nano-platform for precision treatment of acute lung injury via synergistic anti-inflammation and oxidative stress modulation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute lung injury (ALI) remains life-threatening conditions lacking effective disease-modifying therapies. Dysregulated inflammation, oxidative stress, and apoptosis form a self-amplifying pathogenic loop that drives alveolar-capillary barrier disruption, highlighting the urgent need for multifunctional therapeutic strategies. Here, we report a pH-responsive biomimetic nanoplatform, pDA/Esc@ZIF-8, for precision treatment of ALI. Zeolitic imidazolate framework-8 (ZIF-8) was employed to encapsulate the natural anti-inflammatory and antioxidant agent esculin (Esc), while a polydopamine (pDA) coating conferred enhanced colloidal stability, intrinsic reactive oxygen species scavenging activity, and pH-triggered drug release, enabling efficient pulmonary accumulation and sustained local retention. In vitro and in vivo ALI models demonstrated that pDA/Esc@ZIF-8 markedly alleviated lung inflammation, oxidative injury, and epithelial apoptosis, thereby preserving alveolar-capillary barrier integrity and improving respiratory function. Mechanistically, the therapeutic effects were closely associated with modulation of the PI3K/AKT/GSK3β signaling axis, leading to suppression of pro-inflammatory responses, attenuation of oxidative stress, and inhibition of mitochondria-dependent apoptotic pathways. Collectively, this multifunctional nanotherapeutic system integrates pulmonary priority accumulation, microenvironment-responsive release, and pathway-level regulation to interrupt the inflammation-oxidative stress-apoptosis cascade, offering a promising and translatable strategy for the treatment of ALI and related inflammatory lung diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.